In this Conversations in IFN-y podcast episode, emerging data from the 2024 ACR meeting is discussed, highlighting advancements in understanding genetic drivers, cytokine dynamics, and biomarkers like IL-18 and CXCL9 for improved diagnosis and monitoring. Expert insights explore new findings on liver and lung pathology in MAS, as well as updates on therapeutic innovations, including JAK inhibitors and emapalumab, and their roles in enhancing patient outcomes. Practical strategies are provided for integrating the latest research and cutting-edge diagnostics into clinical practice.

Launch Date: December 19, 2024

Release Date: December 19, 2024

Expiration Date: November 30, 2025

FACULTY

Pui Lee, MD

Assistant Professor of Pediatrics

Boston Children's Hospital

Alexei Grom, MD

Professor of Pediatrics

Research Director

Division of Rheumatology

Cincinnati Children’s Hospital Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In Highlights and Hindsight in CLL, Dr. Matthew Davids will describe the most significant ongoing studies and publications in CLL from 2024 and will detail their impact on the treatment continuum. This activity will enable participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.

Launch Date: December 18, 2024

Release Date: December 18, 2024

Expiration Date: November 30, 2025

FACULTY

Matthew Davids, MD, MMSc

Director of Clinical Research, Division of Lymphoma

Dana-Farber Cancer Institute

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.

Launch Date: December 16, 2024

Release Date: December 16, 2024

Expiration Date: November 30, 2025

FACULTY

Naval Daver, MD

Director, Leukemia Research Alliance Program,

Professor of Medicine

Department of Leukemia

MD Anderson Cancer Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link prior to listening to this podcast.

Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.

Launch Date: December 12, 2024

Release Date: December 12, 2024

Expiration Date: November 30, 2025

FACULTY

Guy Young, MD

Professor of Pediatrics

University of Southern California Keck School of Medicine

Director, Hemostasis and Thrombosis Center

Children’s Hospital Los Angeles

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/clinical-clips-in-hemophilia-cutting-edge-advances-presented-at-ash-2024-1

This third podcast episode in the series explores advanced understanding of primary hemophagocytic lymphohistiocytosis (HLH), focusing on its genetic basis, diagnostic innovations, and treatment strategies. The discussion highlights the pathophysiology of HLH as an interferon gamma (IFN-γ) driven disease, emphasizing the role of novel diagnostic tools such as flow cytometry and genetic panels. The panel also examines emerging therapies, including JAK inhibitors and IFN-γ monoclonal antibody (emapalumab), in improving outcomes for both primary and secondary HLH. Practical insights into balancing immunosuppression with efficacy offer guidance for optimizing patient care.

Launch Date: December 2, 2024

Release Date: December 2, 2024

Expiration Date: November 30, 2025

FACULTY

Scott Canna, MD

Assistant Professor of Pediatrics

Childrens Hospital of Philadelphia

Pui Lee, MD

Assistant Professor of Pediatrics

Boston Childrens Hospital

Ashish Kumar, MD, PhD

Professor of Pediatrics

Cincinnati Children’s Hospital Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Launch Date: November 25, 2024

Release Date: November 25 2024

Expiration Date: October 31, 2025

FACULTY

Scott Canna, MD

Assistant Professor of Pediatrics

Childrens Hospital of Philadelphia

Pui Lee, MD

Assistant Professor of Pediatrics

Boston Childrens Hospital

Ashish Kumar, MD, PhD

Professor of Pediatrics

Cincinnati Children’s Hospital Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Launch Date: November 18, 2024

Release Date: November 18, 2024

Expiration Date: October 31, 2025

FACULTY

Scott Canna, MD

Assistant Professor of Pediatrics

Childrens Hospital of Philadelphia

Pui Lee, MD

Assistant Professor of Pediatrics

Boston Childrens Hospital

Ashish Kumar, MD, PhD

Professor of Pediatrics

Cincinnati Children’s Hospital Medical Center

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.

Launch Date: October 1, 2024

Release Date: October 1, 2024

Expiration Date: September 30, 2025

FACULTY

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center

Chief Medical Officer, International Myeloma Foundation

Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute

Adjunct Professor, College of Health Solutions, Arizona State University

Caitlin Costello, MD

Clinical Professor of Medicine

Director, Multiple Myeloma Program

Division of Blood and Marrow Transplantation

Moores Cancer Center

UC San Diego

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/relapsedrefractory-multiple-myeloma-podcast-series-clinical-viewpoints-to-individualize-bispecific-antibody-therapy

Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.

Launch Date: October 1, 2024

Release Date: October 1, 2024

Expiration Date: September 30, 2025

FACULTY

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center

Chief Medical Officer, International Myeloma Foundation

Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute

Adjunct Professor, College of Health Solutions, Arizona State University

Caitlin Costello, MD

Clinical Professor of Medicine

Director, Multiple Myeloma Program

Division of Blood and Marrow Transplantation

Moores Cancer Center

UC San Diego

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/relapsedrefractory-multiple-myeloma-podcast-series-clinical-viewpoints-to-individualize-bispecific-antibody-therapy

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Launch Date: July 19, 2024

Release Date: June 26, 2024

Expiration Date: June 30, 2025

FACULTY

Robert Orlowski, MD, PhD

Professor of Medicine

Director, Section of Myeloma

The University of Texas, MD Anderson Cancer Center

Noopur Raje, MD

Director, Center for Multiple Myeloma

Massachusetts General Hospital

Peter Voorhees, MD

Chief, Plasma Cell Disorders Division

Atrium Health / Levine Cancer Institute

Clinical Professor of Medicine

Wake Forest University School of Medicine

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43